International Journal of Pharmaceutical research and Applications
Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494

Pharmaceutical Cleaning Validation: A Comprehensive Review of Strategies, Regulations, And Analytical Techniques

Mayuri More[1*], Shrikrishna Baokar[2], Rajendra Patil[3]
[1]*Department of Pharmaceutical Quality Assurance, Delonix Society's Baramati Collage of Pharmacy, Barhanpur, Tal- Baramati, Dist- Pune, Maharashtra, India 413102*
[2]*Department of Pharmaceutical Analysis, Delonix Society's Baramati Collage of Pharmacy, Barhanpur, Tal- Baramati, Dist- Pune, Maharashtra, India 413102*
[3]*Department of Pharmaceutical Chemistry, Delonix Society's Baramati Collage of Pharmacy, Barhanpur, Tal- Baramati, Dist- Pune, Maharastra, India 413102*

Date of Submission: 20-07-2025 Date of acceptance: 02-08-2025

ABSTRACT
In pharmaceutical manufacturing, contamination and cross-contamination pose significant risks to product quality, patient safety, and regulatory compliance. These risks primarily arise from inadequate cleaning of equipment, processing areas, or handling of starting materials. Implementing robust cleaning validation protocols minimizes such risks by ensuring that manufacturing equipment is consistently cleaned to predefined and acceptable levels.
Cleaning validation is an essential element of Good Manufacturing Practice (GMP) and provides documented evidence that a cleaning procedure is effective, reproducible, and compliant with regulatory standards. This review highlights the various cleaning approaches employed in the pharmaceutical industry and the strategies used for validating those procedures. Critical parameters, sampling methods, and worst-case scenarios are evaluated to verify cleaning efficiency, reduce variability, and maintain consistent quality assurance throughout the manufacturing process.

Keywords: Cleaning validation, contamination, clean-in-place (CIP), clean-out-of-place (COP), swab sampling, worst-case scenario

I. INTRODUCTION: (1-5)

Cleaning Validation: Definition, Importance, Objectives, and Advantages

Validation refers to a documented process that provides a high level of assurance that a specific procedure, process, equipment, or system consistently produces a product meeting its pre-established quality attributes and specifications. In the context of pharmaceutical manufacturing, *cleaning validation* is defined as the documented evidence that a cleaning procedure consistently removes residues of active pharmaceutical ingredients (APIs), excipients, microbial contaminants, and cleaning agents to predetermined acceptable levels [1,2].
Cleaning, in this regard, involves making equipment, surfaces, and environments free from visible and invisible contaminants such as dust, residues, stains, and other unwanted matter. Cleaning validation is particularly critical for shared manufacturing facilities or multiproduct equipment, where residue carryover from one batch or product could result in cross-contamination or adulteration of subsequent batches.
The process typically includes the development of cleaning methods, assessment of worst-case scenarios, establishment of acceptance criteria, and verification using appropriate analytical techniques to quantify residuals and ensure reproducibility [3].

Significance of Cleaning Validation

The primary purpose of cleaning validation is to prevent cross-contamination between different pharmaceutical products, thereby ensuring product integrity and patient safety. By verifying the effectiveness of cleaning procedures, it provides assurance that no active ingredient or cleaning agent from a previous batch remains on equipment that could adulterate subsequent products [4].
Regulatory bodies such as the US FDA, WHO, and EMA require validated cleaning processes as part of current Good Manufacturing Practices (cGMP). Failure to comply can result in regulatory penalties, product recalls, or harm to patients.

International Journal of Pharmaceutical research and Applications
Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494

Scenarios Requiring Cleaning Validation [5]
Cleaning validation is essential under the following circumstances:

1. During the initial qualification of a cleaning method or equipment.
2. When significant changes are made to an existing cleaning process.
3. If there are changes in the master manufacturing formula or processing steps.
4. Upon the introduction of a new cleaning agent or detergent.
5. When new products are introduced into existing manufacturing equipment.

Objectives of Cleaning Validation

- To ensure product purity and safety for the end user.
- To comply with internal quality assurance systems and regulatory expectations.
- To prevent contamination, cross-contamination, or adulteration during manufacturing.
- To provide scientific rationale and documentation for cleaning effectiveness.
- To support continuous process improvement and lifecycle management of cleaning procedures.

Advantages of Cleaning Validation [6]

- Provides assurance of product **quality** and **safety**.
- Maintains **integrity of batches**, preventing contamination or mix-ups.
- Ensures **microbial and cross-contamination control**.
- Improves **regulatory compliance** with global standards.
- Reduces the cost of **quality failures**, including batch rejection or recalls.
- Promotes **operational efficiency** and **good business practices**.
- Builds **patient trust** and protects brand reputation.

Mechanisms of Contamination [8,9]
Effective cleaning validation must account for the various mechanisms through which contamination can occur in pharmaceutical manufacturing environments. These contaminants may be chemical, biological, or particulate in nature and can compromise product safety, efficacy, and compliance.

1. Cross-Contamination with Active Pharmaceutical Ingredients (APIs)
Cross-contamination occurs when residual APIs from a previously manufactured batch are unintentionally transferred to a subsequent product. This contamination may occur due to insufficient cleaning of shared manufacturing equipment or failure to follow proper cleaning procedures. The presence of residual APIs, excipients, or microbial contaminants in a new batch may adversely affect product quality, leading to potential therapeutic failure or adverse reactions in patients [8,9].

2. Contamination by Cleaning Agents
While cleaning agents are essential for the removal of residues, they can themselves become a source of contamination if not adequately selected or removed. Non-ionic detergents are commonly employed due to their low toxicity and efficacy; however, variability in formulation among suppliers can pose challenges. Incomplete removal of cleaning agents or the use of incompatible cleaning chemicals may result in residual contamination, potentially affecting product safety and violating regulatory limits. Therefore, cleaning agents must be carefully evaluated for their chemical composition, solubility, residue profile, and compatibility with manufacturing surfaces [9].

3. Contamination by Miscellaneous Foreign Materials
Mechanical components and cleaning tools can introduce foreign particulate matter during equipment cleaning or handling. Sources of such contamination include fibers from paper or micron filters, bristles from brushes, cotton threads from wiping cloths, rubber particles from gloves, and sponge fragments. These materials may not only interfere with product quality but can also compromise the analytical testing or validation of cleaning effectiveness.

Cleaning Method Development [10]
Cleaning method development is a critical component of the pharmaceutical validation lifecycle and is carried out alongside drug development to ensure that cleaning processes are scientifically sound, efficient, and compliant with regulatory expectations.

Stages of Cleaning Method Development
Cleaning method development typically progresses through three main stages:

1. **Feasibility**: This stage evaluates whether the proposed method is suitable for the specific sample, equipment, and contaminants in question.
2. **Development**: Optimization of cleaning parameters such as time, temperature, cleaning agents, and equipment to achieve maximum residue removal.

International Journal of Pharmaceutical research and Applications
Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494

3. **Validation**: Demonstration that the optimized cleaning method consistently meets acceptance criteria across multiple runs and conditions.

Objectives of Cleaning Method Development

- To ensure effective removal of product residues, cleaning agents, and other contaminants.
- To establish a reproducible and validated cleaning process that guarantees consistency.
- To minimize the risk of cross-contamination and ensure compliance with international regulatory guidelines, including those from the US FDA, WHO, and ICH.
- To provide scientific justification for the choice of cleaning agents, equipment, and analytical techniques used in the cleaning validation protocol.

General Principles of Cleaning Method Development

Cleaning method development must be grounded in a systematic, science-based approach that ensures the removal of residues while maintaining operational efficiency and regulatory compliance. The following principles guide the development of robust and effective cleaning methodologies in pharmaceutical manufacturing:

1. Risk-Based Approach

A risk-based strategy is fundamental to cleaning validation. It involves identifying and prioritizing equipment, surfaces, or products that pose a higher risk of contamination or cross-contamination. This approach allows the validation team to focus resources and attention on critical areas where product safety or quality may be most vulnerable.

2. Scientific Justification

Every step in the cleaning process must be supported by scientific data and rationale. Selection of cleaning agents, solvents, and cleaning techniques should be based on physicochemical properties of the residues, solubility profiles, and surface interactions. Literature reviews, experimental data, and case studies provide a sound basis for justifying chosen methods.

3. Product and Equipment Considerations

Effective cleaning requires detailed knowledge of the product's characteristics, including solubility, toxicity, degradation potential, and residue behavior. Additionally, equipment design, material composition (e.g., stainless steel, glass, plastic), surface roughness, and accessibility must be considered to optimize cleaning efficiency.

4. Inclusion of Worst-Case Scenarios

Cleaning methods must be validated under worst-case conditions, i.e., using the most difficult-to-clean product, surface, or area. This ensures that the method is robust and effective under all practical manufacturing conditions, thus preventing product contamination under less challenging scenarios.

5. Practicality and Reproducibility

Cleaning procedures must be practical, reproducible, and easy to implement on a routine basis. The method should not be overly complex or time-consuming and must be designed for consistency across operators and production cycles. Moreover, it should balance efficacy with economic feasibility and safety for both the product and personnel.

6. Environmental Safety and Sustainability

Cleaning agents should be selected with environmental sustainability in mind. Where possible, biodegradable and non-toxic substances should be used to minimize environmental impact and ensure safety during disposal. Compliance with local and international environmental regulations should also be considered during method development.

Key Strategies for Cleaning Method Development

An effective cleaning method must be strategically developed by integrating scientific rationale, equipment-specific factors, and regulatory requirements. The following strategies provide a systematic framework for designing, optimizing, and validating cleaning procedures in pharmaceutical manufacturing:

1. Assessment of Product and Equipment Characteristics

Understanding the physicochemical properties of the product is essential for effective cleaning method development. Parameters such as drug solubility, potency, toxicity, and residue behavior on surfaces must be characterized. Simultaneously, a thorough assessment of equipment design—including material composition (e.g., stainless steel, glass), surface finish, and complexity—helps identify critical areas that may require specialized cleaning approaches.

2. Selection of an Appropriate Cleaning Agent

The choice of cleaning agent should be based on the chemical nature of the product residues and the surface compatibility of the equipment. Cleaning agents may be acidic, alkaline, neutral, or enzymatic, and each category has specific advantages depending on the residue type. The selected agent must be effective in dissolving or dislodging residues while remaining safe for operators, the environment, and the equipment surfaces.

3. Definition of Critical Cleaning Parameters

Cleaning parameters such as time, temperature, mechanical action, agent concentration, and contact time should be optimized and controlled. These

International Journal of Pharmaceutical research and Applications
Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494

variables influence the efficiency of residue removal and should be determined through experimental studies, particularly for worst-case scenarios and hard-to-clean surfaces. A risk-based approach is recommended for defining parameter ranges and targeting critical process points.

4. Establishment of Acceptance Criteria

Acceptance limits for cleaning validation must be scientifically justified and aligned with toxicological and pharmacological data. Calculations such as Maximum Allowable Carryover (MACO) and No-Observed-Effect Level (NOEL) are typically used to define residue limits. Regulatory guidance documents—including those issued by the FDA, WHO, and ICH Q7—provide standardized methodologies for determining and justifying these limits.

5. Development and Validation of Analytical Methods

Sensitive and specific analytical techniques are required to detect and quantify trace residues on cleaned surfaces. Commonly used methods include ultraviolet (UV) spectroscopy, total organic carbon (TOC) analysis, and high-performance liquid chromatography (HPLC). These methods must be validated according to ICH Q2 guidelines, ensuring accuracy, precision, linearity, specificity, and sensitivity.

Cleaning Agents in Pharmaceutical Manufacturing [10]

Cleaning agents are chemical substances specifically formulated to remove active pharmaceutical ingredients (APIs), excipients, microorganisms, and other contaminants from equipment, surfaces, and environments used in pharmaceutical production. They play a critical role in maintaining hygienic conditions, preventing cross-contamination, and ensuring compliance with current Good Manufacturing Practices (cGMP) and other regulatory standards.

Selection Criteria for Cleaning Agents

The selection of an appropriate cleaning agent depends on multiple factors, including:

- **Nature of the Residue**: Characteristics such as solubility, pH sensitivity, chemical reactivity, and adhesion of the residues (e.g., APIs, excipients, degradation products).
- **Surface Material of Equipment**: Compatibility with the construction materials such as stainless steel, glass, or plastic is essential to prevent corrosion or surface degradation.
- **Cleaning Process Requirements**: Suitability for clean-in-place (CIP), clean-out-of-place (COP), or manual cleaning processes.

Desirable Properties of Cleaning Agents

An ideal cleaning agent for pharmaceutical use should meet the following criteria:

a) **Non-reactivity**: It should not chemically react with the product residues or degrade the active ingredients.

b) **Equipment Compatibility**: It must not corrode or damage the surfaces or parts of the manufacturing equipment.

c) **Environmental Safety**: It should be biodegradable and environmentally safe, minimizing hazardous waste disposal concerns.

d) **Residue-Free**: It should not remain on the equipment surfaces post-cleaning or contribute to contamination of subsequent batches.

e) **Ease of Removal**: It should be readily rinsed off using water or a suitable solvent, leaving minimal detectable residues.

f) **Non-toxicity and Availability**: The agent should be safe for operators, non-toxic under residual conditions, and economically viable and readily available for routine use.

Types of Cleaning Agents

Cleaning agents used in pharmaceutical industries can be broadly classified based on their chemical nature and mechanism of action:

- **Acidic Cleaners**: Effective against mineral deposits and inorganic residues; commonly used for removing scales or metal oxides.
- **Alkaline Cleaners**: Useful for dissolving organic residues such as fats, proteins, or API formulations; typically composed of sodium or potassium hydroxide.
- **Neutral Cleaners**: Milder formulations suitable for general cleaning of sensitive equipment or surfaces.
- **Enzymatic Cleaners**: Contain enzymes such as proteases or amylases that break down specific organic contaminants.
- **Solvent-Based Cleaners**: Used to remove residues that are insoluble in water; include alcohols, ketones, or other organic solvents.

The choice among these depends on the specific cleaning challenge, the nature of the contamination, and regulatory and safety considerations.

Types of Cleaning Methods in Pharmaceutical Manufacturing

Cleaning methods in the pharmaceutical industry are selected based on the nature of the equipment, type of residue, level of contamination, and cleaning validation requirements. These methods are broadly classified into automated, semi-automated, and manual approaches, each having its own advantages, limitations, and validation considerations.

International Journal of Pharmaceutical research and Applications
Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494

1. Clean-In-Place (CIP)

Clean-In-Place is an automated cleaning method that allows internal surfaces of equipment (e.g., tanks, piping systems, reactors) to be cleaned without disassembly. The process involves circulating or spraying cleaning solutions through the system under defined conditions.

Types of CIP Systems:

- **Single-Pass Systems**: Fresh cleaning solution is introduced for each cleaning cycle and discarded after use. These systems ensure high cleaning efficiency but consume more resources.
- **Recirculation Systems**: Cleaning solution is reused after filtration and analysis. These systems are more economical but require careful validation to prevent cross-contamination.

Advantages:

- Reduces manual labor and human error.
- Minimizes downtime between production batches.
- Highly reproducible and easily validated.

Limitations:

- High initial investment.
- Less effective for complex or irregular equipment geometries.

2. Clean-Out-of-Place (COP)

In Clean-Out-of-Place systems, parts of equipment are disassembled and cleaned in a separate cleaning area using immersion tanks, spray jets, or washing machines.

Advantages:

- Effective for components that are difficult to clean in place.
- Allows for visual inspection after cleaning.

Limitations:

- Labor-intensive.
- Risk of contamination during transportation of parts.

3. Manual Cleaning

Manual cleaning involves physically scrubbing or wiping equipment surfaces using brushes, cloths, mops, or other tools along with appropriate cleaning agents.

Advantages:

- Suitable for small-scale equipment or areas inaccessible by automated systems.
- Simple and low-cost.

Limitations:

- High operator variability and labor dependency.
- Difficult to validate consistently.
- Increased risk of human error and contamination.

4. Semi-Automated Cleaning

Semi-automated cleaning combines elements of manual and automated methods. For example, certain parts may be manually removed and cleaned before initiating an automated CIP cycle.

Advantages:

- Flexibility in cleaning complex systems.
- Balances automation with human control.

Limitations:

- Requires careful coordination and documentation of both manual and automated steps.
- May introduce inconsistencies if not properly validated.

5. Fully Automated Cleaning

Fully automated systems are programmable and require minimal human intervention. The cleaning process follows a defined cycle of pre-rinse, detergent wash, post-rinse, and drying, with all parameters controlled and monitored automatically.

Advantages:

- High reproducibility and regulatory compliance.
- Reduces operator exposure to hazardous cleaning agents.
- Enhances process control and documentation.

Limitations:

- High installation and maintenance costs.
- Not suitable for all types of equipment.

Sampling Methods in Cleaning Validation [11–15]

Sampling methods play a critical role in evaluating the effectiveness of cleaning procedures by detecting residual contaminants on equipment surfaces. Samples are typically collected from critical or "worst-case" locations that are most difficult to clean and represent potential hotspots for residue accumulation. Sampling techniques are selected based on the type of equipment, nature of the residue, and regulatory expectations.

1. Swab Sampling (Direct Sampling) [12,13]

Swab sampling is the most widely used and accepted direct sampling technique in cleaning validation. It involves the use of a swab composed of fibrous material (typically polyester or cotton) mounted on a plastic handle.

Procedure:

1. Identify worst-case locations or hard-to-clean areas on the equipment.
2. Visually inspect the surface to ensure it is free of visible contamination before sampling.
3. Pre-wet the swab with a solvent in which the analyte is soluble.

International Journal of Pharmaceutical research and Applications
Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494

4. Gently press the swab against the inner wall of a vial to remove excess solvent, minimizing extractables.
5. Swab the defined surface area using a prescribed pattern (e.g., horizontal, vertical, diagonal).
6. Insert the swab head into a sample vial by breaking it along the notched handle.
7. Label the sample and send it for analytical evaluation.

Advantages:
- Capable of detecting both chemical and microbial contaminants.
- Effective for recovering poorly soluble or adhesive residues.
- Enables targeted sampling of specific, high-risk locations.

Limitations:
- Insertion of fibrous material from the swab may introduce artifacts.
- Challenging to apply in large-scale or complex equipment (e.g., long piping systems, reactors).
- Swabbing internal surfaces of closed systems may be impractical.

2. Rinse Sampling (Indirect Sampling) [14,15]

Rinse sampling is an indirect method used to assess the cleanliness of internal equipment surfaces that are difficult to access directly, such as piping or enclosed vessels.

Procedure:
1. Develop a standard operating procedure (SOP) considering the equipment's design, shape, and capacity.
2. Select an appropriate rinsing solvent, typically water or an approved solvent with known recovery.
3. Collect a sample from the final rinse during the cleaning cycle.
4. Alternatively, fill the system with rinsing solvent, agitate, and collect the bulk solution for analysis.

Advantages:
- Covers a large surface area in a single sample.
- Useful for equipment that cannot be easily dismantled.
- Simple and less operator-dependent compared to swabbing.

Limitations:
- May dilute residues, reducing sensitivity.
- Uneven distribution of residues can lead to inaccurate results.
- Location-specific residue identification is not possible.
- Insoluble residues may not be detected.

3. Placebo Sampling

Placebo sampling involves the use of a placebo batch, which is passed through the same equipment pathways as the drug product. The placebo, composed of the same excipients but lacking the active ingredient, serves as a surrogate to capture residual drug substances.

Rationale:

The assumption is that residual APIs will be adsorbed or carried away by the placebo during its passage through the equipment. Analysis of the placebo can provide indirect evidence of cleaning effectiveness.

Advantages:
- Practical for continuous processes and pipeline systems.
- Non-invasive sampling of residue removal.

Limitations:
- Interpretation may be difficult due to excipient interferences.
- Less precise for localized contamination.

4. Direct Analytical Surface Sampling

Advanced analytical techniques such as Fourier-Transform Infrared (FTIR) Spectroscopy or X-ray Photoelectron Spectroscopy (XPS) can be used for real-time, direct analysis of equipment surfaces.

These techniques detect chemical residues by identifying their specific spectral signatures without physically removing the sample.

Advantages:
- Combines sampling and analysis in a single step.
- Non-destructive and rapid.

Limitations:
- Limited to flat, accessible surfaces.
- Requires specialized equipment and trained personnel.
- Cannot provide bulk residue quantification.

Levels or Degrees of Cleaning in Pharmaceutical Manufacturing

The extent and rigor of cleaning required for pharmaceutical manufacturing equipment are determined by several critical factors. These include:
- **Physicochemical nature of the contaminant**, such as solubility and toxicity.
- **Equipment utilization**, specifically whether it is dedicated to a single product or shared across multiple products.
- **Stage of the manufacturing process**, whether initial, intermediate, or final.

International Journal of Pharmaceutical research and Applications
Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494

- **Type of changeover**, including batch-to-batch or product-to-product transitions.

Cleaning processes must be validated to the appropriate level depending on these parameters, with higher-risk situations necessitating more stringent controls and validation procedures.

Level 1 Cleaning

Level 1 cleaning applies to scenarios involving the **manufacture of multiple batches of the same product** in succession using the same equipment. For example, when producing four consecutive batches of paracetamol (Batch 1 through Batch 4), cleaning between batches may involve only routine procedures aimed at maintaining consistent product quality rather than comprehensive validation efforts.

Characteristics:

- Typically involves less rigorous cleaning.
- Does not require complete residue removal as there is no risk of cross-product contamination.
- Often handled by standard operating procedures (SOPs) without extensive documentation or analytical testing.

Level 2 Cleaning

Level 2 cleaning is required when equipment is used to manufacture **different products** or when there is a **significant time gap or formulation change** between batches of the same product. This includes product-to-product changeover or cleaning at the end of a campaign before introducing a new drug formulation.

Characteristics:

- Involves thorough and validated cleaning procedures.
- Requires analytical verification (e.g., swab or rinse sampling) to ensure removal of all potential residues.
- Includes stricter acceptance criteria and documentation to confirm compliance with GMP and regulatory standards.

Establishing Acceptance Criteria Based on NOEL and MACO (16-18)

In pharmaceutical cleaning validation, setting scientifically justified acceptance criteria is essential to ensure that any residual active pharmaceutical ingredient (API) remaining on manufacturing equipment does not pose a risk to patient health. Two key toxicological parameters used to establish these limits are the No-Observed-Effect Level (NOEL) and the Maximum Allowable Carryover (MACO).

1. No-Observed-Effect Level (NOEL)

The NOEL is defined as the highest dose of a pharmaceutical compound at which no adverse effects are observed in test subjects, typically animals, under specified experimental conditions. It is a foundational toxicological value used to estimate safe exposure levels in humans.

The NOEL for a drug is often calculated using its Lethal Dose 50 (LD_{50}), which is the dose required to cause death in 50% of the tested animal population. The calculation assumes an average adult human weight of 70 kg and includes a conservative safety margin:

$$\mathbf{NOEL} = \frac{LD_{50} \times 70\ \text{kg}}{2000}$$

Where:

- **LD_{50}** = Lethal dose in mg/kg (from animal studies)
- **70 kg** = Average adult human body weight
- **2000** = Safety constant derived from toxicological risk assessments

2. Maximum Allowable Carryover (MACO)

The **MACO** is the calculated limit of residual drug that can be carried over into the next product manufactured in shared equipment, without causing any adverse health effects. It is expressed in milligrams or parts per million (ppm) and is used to set acceptable residue levels in cleaning validation protocols.

$$\mathbf{MACO} = \frac{\text{NOEL} \times \text{MBS}}{\text{SF} \times \text{TDD}}$$

Where:

- **NOEL** = No-Observed-Effect Level (mg/day)
- **MBS** = Maximum batch size of the next product (mg or kg)
- **SF** = Safety factor (usually 1000 for oral products)
- **TDD** = Total Daily Dose of the next product (mg/day)

This calculation ensures that any residual amount of the previous product does not exceed a safe exposure level when ingested as part of the next product's total daily dose.

Validation Protocol for Cleaning Procedures

A Validation Protocol is a predefined, formally approved document that outlines the specific items, activities, responsibilities, and acceptance criteria involved in a cleaning validation study. It serves as the operational blueprint for demonstrating that a cleaning process consistently yields equipment that is suitable for reuse in pharmaceutical production.

It is recommended that every organization maintain a Master Validation Plan (MVP), which defines the

International Journal of Pharmaceutical research and Applications
Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494

overarching validation strategy for a facility, including product lines, equipment types, and cleaning strategies. Each protocol should be prepared, reviewed, and approved before the initiation of validation activities and should include or reference the following essential components:

1. **Background Information**: Justification and rationale for performing the validation.
2. **Purpose**: Objective of the cleaning validation study.
3. **Scope**: Description of the equipment, processes, products, and manufacturing areas covered.
4. **Roles and Responsibilities**: Identification of personnel responsible for protocol execution, sample collection, analysis, and report preparation.
5. **Sampling and Analytical Methods**: Detailed procedures for residue sampling (e.g., swab or rinse) and the analytical techniques to be employed.
6. **Acceptance Criteria**: Scientifically justified limits based on toxicological data (e.g., MACO, NOEL).
7. **Change Control Requirements**: Provisions for managing changes to equipment, processes, or cleaning agents.
8. **Deviation Handling**: Procedures for documenting, investigating, and addressing deviations encountered during the validation study.

Cleaning Validation Report

Upon completion of the cleaning validation study, a **Validation Report** must be generated and formally approved. This report provides comprehensive documentation of the study's outcomes and demonstrates whether the cleaning process meets predefined acceptance criteria.

The report should include the following elements:

a. **Summary or Reference to Procedures**: A concise description or cross-reference to the SOPs used for cleaning, sampling, and analytical testing.

b. **Results and Observations**: Detailed presentation of physical and analytical data obtained during the study, along with any significant observations or anomalies.

c. **Recommendations**: Based on results, the report may include recommendations for improvements, corrective actions, or revalidation requirements.

d. **Conclusions**: A clear statement of whether the cleaning process meets the acceptance criteria and is validated for its intended purpose.

e. **Approval Signatures**: Formal approval from authorized personnel including Quality Assurance, Validation, and Production departments.

f. **Deviation Review**: Documentation and assessment of any deviations from the protocol, along with their impact and resolutions.

g. **Interim Reporting**: If ongoing production is not expected, interim reports may be issued batch-wise until the cleaning process is fully validated across all required scenarios.

Revalidation of Cleaning Procedures [19,20]

Revalidation is a critical component of the cleaning validation lifecycle. It ensures that validated cleaning procedures remain effective following significant changes or events that may affect the cleaning outcome.

Revalidation is required under the following circumstances:

a. **Replacement of Equipment**: Introduction of new equipment or replacement of existing units.

b. **Major Equipment Modifications**: Structural or functional changes in equipment design or configuration.

c. **Changes in Cleaning SOPs**: Updates or modifications to standard cleaning procedures, including agents or techniques.

d. **Introduction of New Products or Processes**: Manufacturing of a new product on shared equipment.

e. **Failure to Meet Acceptance Criteria**: Any deviation from predefined residue limits during routine monitoring or validation.

Revalidation can be full or partial, depending on the extent of the change and the potential risk to product quality and patient safety. Documentation and regulatory compliance are essential in all revalidation activities.

II. Conclusion

Cleaning validation is a critical component of quality assurance in pharmaceutical manufacturing, ensuring that equipment is consistently cleaned to levels that prevent contamination and cross-contamination. A well-designed and properly executed cleaning validation program provides documented evidence that the cleaning procedures are effective, reproducible, and compliant with regulatory expectations.

By minimizing the risk of carryover from active pharmaceutical ingredients (APIs), excipients, cleaning agents, or microbial contaminants, cleaning validation enhances product safety, maintains batch integrity, and safeguards patient health. It also contributes to continuous process improvement, operational efficiency, and customer trust.

Ultimately, cleaning validation reinforces the pharmaceutical industry's commitment to Good

Manufacturing Practices (GMP) and ensures that medicinal products meet the highest standards of quality, safety, and efficacy.

References

[1]. Rajpal G, Arya RKK, Joshi T, Bisht D. A review on cleaning validation in pharmaceutical industry. *J Drug Deliv Ther.* 2018;8(3):138–46.
[2]. Murthy DN, Chitra K. A review article on cleaning validation. *Int J Pharm Sci Res.* 2013;4(9):3317–27.
[3]. Khan F, Khan AS, Rao N. A review on cleaning validation. *Int J Res Pharm Chem.* 2020;10(2):205–14.
[4]. Kailaschand AM. Process validation of cephalosporin antibiotics cefuroxime axetil 500 mg tablets [dissertation]. Karnataka: Rajiv Gandhi University of Health Sciences; 2011.
[5]. Kumar VS, Sanjeev T. Overview of cleaning validation in pharmaceutical manufacturing unit. *Int J Adv Res Pharm Bio Sci.* 2012;1(2):154–64.
[6]. Fredrick R. The basic facts of cleaning validation. *Pharmainfo.net* [Internet]. 2004 [cited 2025 Jul 24]. Available from: http://www.pharmainfo.net/reviews/basic-facts-cleaning-validation
[7]. Patel HP, et al. Process validation of Benazepril HCL 5 mg tablet. *Int Res J Pharm Appl Sci.* 2012;2(4):1–16.
[8]. Kathiresan K. Cleaning validation of acetaminophen tablets. *Rasayan J Chem.* 2010;3(3):503–6.
[9]. Nash RA, Wachter AH. *Pharmaceutical Process Validation*. 3rd ed. New York: Marcel Dekker; 2003. p. 793–820.
[10]. Pharmasubject.com. Cleaning validation bracketing worst case [Internet]. 2016 [cited 2025 Jul 24]. Available from: https://www.pharmasubject.com/2016/09/cleaning-validation-bracketing-worst.html
[11]. Nassani M. Cleaning validation in pharmaceutical industry. *J Validation Technol.* 2005;38–58.
[12]. Yang P, Burson K, Feder D, MacDonald F. Method development of swab sampling for cleaning validation of a residual active pharmaceutical ingredient. *Pharm Technol.* 2005;86–94.
[13]. Rached FA, Valerie M, Bayon IL, Perrine GP, Koska M, Feder M. Methods for recovering microorganisms from solid surfaces used in the food industry: a review. *Int J Environ Res Public Health.* 2013;10(11):6169–83.
[14]. GMP SOP. Cleaning validation: swab vs rinse [Internet]. Available from: https://www.gmpsop.com/articles/article001.html
[15]. WeSRCH. Cleaning validation in pharma [Internet]. Available from: https://www.wesrch.com/medical/docxME1XXFEGSEOHD
[16]. World Health Organization. *Good manufacturing practices: quality assurance of pharmaceuticals*. Geneva: WHO; 2016.
[17]. Chitra K, Murthy DN. A review article on cleaning validation. *Int J Pharm Sci Res.* 2013;4(9):3317–27.
[18]. Pharmaguideline. NOEL and MACO calculation in cleaning validation [Internet]. Available from: https://www.pharmaguideline.com/2015/01/NOEL-and-MACO-calculation-in-cleaning-validation.html
[19]. World Health Organization. *Guidelines on validation* [Internet]. Working Document QAS/16.666; 2016. Available from: http://www.who.int/medicines/areas/quality_safety/quality_assurance/validation
[20]. Parajuli R, Shrestha S, Lamichane S, Pokhrel P. A review on pharmaceutical process validation of solid dosage form (tablets). *J Drug Deliv Ther.* 2015;5(6):1–7. doi:10.22270/jddt.v5i6.1109